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LETTERS TO THE EDITOR
Therapeutic Options for Patients
With Chronic Refractory Angina Pectoris
In their state-of-the-art review, Kim et al. (1) discuss the available
therapeutic options for patients with chronic therapeutically re-
fractory angina pectoris. It is a hopeful perspective, one that offers
new and challenging strategies to these severely disabled “no-
option” patients. However, some criticism regarding the review is
necessary.
First, one of the major problems in evaluating the outcomes of
the different strategies depends on how accurate this heteroge-
neous group of patients is defined (2). Second, with respect to
methodologic issues, we fully agree with the investigators that,
owing to a lack of randomized controlled trials, the efficacy of
adjunct therapies cannot always be evaluated adequately. However,
for both laser and neuromodulation, a placebo effect has been
investigated, making use of randomized designs. Furthermore, the
long-lasting clinical effect of neuromodulation, demonstrated in a
group of 517 patients by TenVaarwerk et al. (3), cannot be
explained by placebo alone. Unfortunately, this study is not cited
correctly, as the outcomes adhere to Creco et al. (4), who reported
on only 23 patients. Moreover, we would stress that a controlled
trial with angiogenic gene therapy has been performed. This study,
entitled “Randomized, Single-Blind, Placebo-Controlled Pilot
Study of Catheter-Based Myocardial Gene Transfer for Thera-
peutic Angiogenesis Using Left Ventricular Electromechanical
Mapping in Patients With Chronic Myocardial Ischemia,” was
published recently by the Vale et al. group from Isner’s group (5).
Third, regarding the mechanisms of action, clinical evidence
that neuromodulation affects the sympathetic outflow is at least
debatable.
Fourth, the investigators claim to give a complete overview on
angiogenesis trials with gene therapy. In this respect, our major
concern is that the researchers may confuse the difference between
gene therapy and recombinant protein therapy. In Table 4 (entitled
“Vascular Gene Therapy Trials”) of the Kim et al. (1) review, two
non-gene therapy trials (i.e., FGF recombinant protein) are
included. This is misleading, because the term “recombinant
adenoviral FGF” is used to indicate a gene therapeutic agent. In
our opinion it would have been more appropriate to deal with all
experimental angiogenic trials and not just the ones dealing with
gene therapy. With respect to the latter, both the hallmark study
by Schumacher et al. (6) and the VIVA trial (7) should have been
cited, as, respectively, the first study on angiogenic therapy in
patients with refractory angina pectoris and as pivotal studies.
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REPLY
We thank Drs. DeJongste, Hautvast, and Tio for their comments
concerning our recent article on refractory angina pectoris. We
agree that defining outcomes regarding treatment modalities is
difficult in this population because of the heterogeneous spectrum
of patients.
Although randomized, placebo-controlled studies have now
been performed using laser revascularization techniques, the data
have been inconsistent in their results, leading to widespread
speculation in the cardiology community regarding the efficacy of
such treatment. There have been no known placebo-controlled
studies investigating neurostimulation techniques. We thank the
correspondents for correctly noting the error in referencing the
data of TenVaarwerk et al. (1) on the long-term outcomes of spinal
cord stimulation. This study, however, was retrospective in nature
and did not have a control arm. A placebo effect cannot be
dismissed simply on grounds of length of follow-up. We agree that
the mechanism of action regarding neurostimulation is debatable.
With regards to the gene therapy section, Table 4 of our article
more correctly should be entitled “Experimental Angiogenic Tri-
als” as noted, although one can argue that the recombinant FGF
proteins are a product of recombinant gene technology and,
therefore, related to traditional gene therapy (2). The term
“recombinant adenoviral FGF” was used correctly in the table, as
the study by Grines et al. (3) was indeed a gene therapy trial. The
placebo-controlled pilot study by Vale et al. (4) did demonstrate
the feasibility and safety of catheter-based gene transfer but only
randomized six patients, and conclusions concerning the potential
of a placebo effect cannot be made from this. The VIVA trial was
first presented in abstract form in the 1998 ACC meetings and has
not been published. We omitted this trial in accordance with
JACC guidelines, which do not recommend citing abstract data
over two years old.
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